WithdrawnPHASE1, PHASE2NCT02228512

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Studying Castleman disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Thomas S Uldrick, M.D.
National Cancer Institute (NCI)
Intervention
Pomalidomide(drug)
Eligibility
18-99 years · All sexes
Timeline
20142015

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02228512 on ClinicalTrials.gov

Other trials for Castleman disease

Additional recruiting or active studies for the same condition.

See all trials for Castleman disease

← Back to all trials